Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...

Also Read: US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...

Drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro ... For example, a liver transplant can cost upwards of $500,000, a cost that could be avoided by addressing obesity early.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...